» Articles » PMID: 35076659

Screening for Atrial Fibrillation: US Preventive Services Task Force Recommendation Statement

Abstract

Importance: Atrial fibrillation (AF) is the most common cardiac arrhythmia. The prevalence of AF increases with age, from less than 0.2% in adults younger than 55 years to about 10% in those 85 years or older, with a higher prevalence in men than in women. It is uncertain whether the prevalence of AF differs by race and ethnicity. Atrial fibrillation is a major risk factor for ischemic stroke and is associated with a substantial increase in the risk of stroke. Approximately 20% of patients who have a stroke associated with AF are first diagnosed with AF at the time of the stroke or shortly thereafter.

Objective: To update its 2018 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review on the benefits and harms of screening for AF in older adults, the accuracy of screening tests, the effectiveness of screening tests to detect previously undiagnosed AF compared with usual care, and the benefits and harms of anticoagulant therapy for the treatment of screen-detected AF in older adults.

Population: Adults 50 years or older without a diagnosis or symptoms of AF and without a history of transient ischemic attack or stroke.

Evidence Assessment: The USPSTF concludes that evidence is lacking, and the balance of benefits and harms of screening for AF in asymptomatic adults cannot be determined.

Recommendation: The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of screening for AF. (I statement).

Citing Articles

Consumer-grade wearable devices in arrhythmia diagnostics for clinicians: where we are and where we are going.

Rytkin E, Zotova I, Passman R, Ardashev A, Trachiotis G, Efimov I J Interv Card Electrophysiol. 2025; .

PMID: 39863724 DOI: 10.1007/s10840-025-01994-0.


State of the art of mobile health technologies use in clinical arrhythmia care.

Sridhar A, Cheung J, Lampert R, Silva J, Gopinathannair R, Sotomonte J Commun Med (Lond). 2024; 4(1):218.

PMID: 39472742 PMC: 11522556. DOI: 10.1038/s43856-024-00618-4.


What Constitutes High Risk for Venous Thromboembolism? Comparing Approaches to Determining an Appropriate Threshold.

Mittman B, Hu B, Schulte R, Le P, Pappas M, Hamilton A medRxiv. 2024; .

PMID: 39252910 PMC: 11383466. DOI: 10.1101/2024.08.30.24312871.


The NORwegian atrial fibrillation self-SCREENing (NORSCREEN) trial: rationale and design of a randomized controlled trial.

Boskovic M, Jortveit J, Haraldsen M, Berge T, Engdahl J, Lochen M Europace. 2024; 26(10).

PMID: 39248170 PMC: 11448330. DOI: 10.1093/europace/euae228.


Actioning atrial fibrillation identified by ambulance services in England: a qualitative exploration.

Wilkinson C, Moloney S, McClelland G, Todd A, Doran T, Price C BMJ Open. 2024; 14(9):e078777.

PMID: 39237274 PMC: 11381708. DOI: 10.1136/bmjopen-2023-078777.